Clinical Trial Details
| Trial ID: | L0566 |
| Source ID: | JPRN-UMIN000023044 |
| Associated Drug: | Canaglifrozin |
| Title: | |
| Acronym: | -- |
| Status: | Not Recruiting |
| Study Results: | No Results Available |
| Results: | -- |
| Conditions: | Nonalcoholic fatty liver disease type 2 diabetes mellitus |
| Interventions: | canaglifrozin 100mg for 12 weeks |
| Outcome Measures: | serum level of ALT at baseline and end of 12 weeks. The change of ALT between baseline and end of 12 weeks administration.serum level of AST, GGT, ALP, HbA1c, fasting glucose, fasting insulin, c peptide, platelet count, uric acid, total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, hyaluronic acid, type 4 collagen 7s. waist circumference, NAFIC score, FIB-4 index, FM-fibro index, body composition, LSM, CAP, DEBQ, SF-8TM |
| Sponsor/Collaborators: | Kyoto prefetural University of Medicine |
| Gender: | All |
| Age: | 20years-old75years-old |
| Phases: | Not applicable |
| Enrollment: | 20 |
| Study Type: | Interventional |
| Study Designs: | Single arm Non-randomized |
| Start Date: | 21/10/2016 |
| Completion Date: | -- |
| Results First Posted: | -- |
| Last Update Posted: | 2 April 2019 |
| Locations: | Japan |
| URL: | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026558 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D058 | Canagliflozin | Chemical drug | DB08907 | SGLT2 inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |